Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share

Equities analysts predict that SAGE Therapeutics Inc (NASDAQ:SAGE) will report earnings per share of ($2.04) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for SAGE Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.79) and the lowest estimate coming in at ($2.35). SAGE Therapeutics reported earnings of ($1.50) per share during the same quarter last year, which would suggest a negative year over year growth rate of 36%. The business is expected to report its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that SAGE Therapeutics will report full-year earnings of ($7.42) per share for the current fiscal year, with EPS estimates ranging from ($7.73) to ($7.16). For the next fiscal year, analysts anticipate that the business will post earnings of ($7.69) per share, with EPS estimates ranging from ($9.08) to ($6.43). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. SAGE Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis.

Several equities research analysts have recently commented on the company. Stifel Nicolaus reissued a “buy” rating and set a $198.00 price target on shares of SAGE Therapeutics in a research note on Friday, December 8th. Needham & Company LLC boosted their price target on SAGE Therapeutics from $86.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, November 10th. BMO Capital Markets reissued a “buy” rating and set a $80.00 price target on shares of SAGE Therapeutics in a research note on Friday, October 27th. Goldman Sachs Group reissued a “buy” rating and set a $87.00 price target on shares of SAGE Therapeutics in a research note on Friday, October 6th. Finally, Chardan Capital raised SAGE Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $60.00 to $140.00 in a research note on Friday, November 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the stock. SAGE Therapeutics presently has an average rating of “Buy” and a consensus target price of $171.21.

Shares of SAGE Therapeutics (SAGE) traded up $2.75 during trading hours on Friday, hitting $169.46. The stock had a trading volume of 369,084 shares, compared to its average volume of 602,377. The stock has a market cap of $6,960.00, a price-to-earnings ratio of -24.67 and a beta of 3.05. SAGE Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $180.83.

In related news, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total value of $33,103,390.15. Following the sale, the chief executive officer now owns 211,473 shares of the company’s stock, valued at approximately $33,296,423.85. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Stephen Kanes sold 44,000 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total value of $7,795,920.00. Following the completion of the transaction, the insider now owns 46,348 shares of the company’s stock, valued at $8,211,938.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 314,247 shares of company stock worth $50,465,110. 6.10% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in SAGE Therapeutics by 11.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares during the last quarter. Hershey Trust Co. acquired a new position in SAGE Therapeutics in the 3rd quarter valued at $118,000. Oppenheimer Asset Management Inc. raised its holdings in SAGE Therapeutics by 412.9% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,565 shares during the last quarter. Bessemer Group Inc. acquired a new position in SAGE Therapeutics in the 3rd quarter valued at $141,000. Finally, Envestnet Asset Management Inc. raised its holdings in SAGE Therapeutics by 70.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,906 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 1,204 shares during the last quarter. Institutional investors own 95.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/19/zacks-brokerages-anticipate-sage-therapeutics-inc-sage-will-announce-earnings-of-2-04-per-share.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply